Almagreño, ahora en Sevilla tras acogerme en Euskadi. Oncología Médica en HUVMacarena.
Joined March 2010
- Tweets2K
- Following476
- Followers174
- Likes946
Alberto Sánchez-Camacho retweeted
🚨 How much adjuvant EV do we really need in MIBC?
Same 3 neoadjuvant EV cycles. Two positive phase III trials. One major difference:
🔹 KEYNOTE-905/EV-303: 6 additional EV cycles after cystectomy
🔹 VOLGA: No adjuvant EV
Peripheral neuropathy: 37% vs 18%.
An absolute difference of 19 percentage points—approximately 1 additional neuropathy event per 6 patients treated.
-> NNH 6!
But ⚠️ these are cross-trial rates, not a randomized comparison. We cannot attribute the difference solely to adjuvant EV.
With curative intent, cumulative neurotoxicity matters.
Could pCR + postoperative ctDNA help identify patients who can safely omit adjuvant EV?
Maximize cures. Minimize unnecessary toxicity. 🔬
#ESMO26 #BladderCancer
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Alberto Sánchez-Camacho retweeted
⚡️ LITESPARK-011 final analysis #ESMO26: belzutifan + lenvatinib vs cabozantinib in advanced ccRCC after anti–PD-(L)1 therapy.
PFS HR 0.74 (14.8 vs 10.8 mo). ORR 53% vs 40%.
OS HR 0.85 — not statistically significant. PFS and ORR benefits maintained at final analysis.
@DrDanielHeng @OncoAlert
#KidneyCancer #ESMO26 #GUOncology
oncodaily.com/genitourinary-…
Alberto Sánchez-Camacho retweeted
My one-slide summary of the key GU oncology trials presented at #ESMO26!
Lots of exciting data and important discussion points across UC, RCC, and prostate cancer.
My personal TOP 3:
🥇 VOLGA
🥈 LITESPARK-011 & 012
🥉 JNJ-6143
What were your highlights from ESMO 2026?
Alberto Sánchez-Camacho retweeted
Six phase III trials. Six different stories.
Higher pCR does not guarantee better survival.
In muscle-invasive bladder cancer, EFS and OS matter more than impressive response rates.
Are we measuring what truly matters to patients?
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @tompowles1 @urologysummit @Uromigos @Uroweb @urotoday
Alberto Sánchez-Camacho retweeted
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.
⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy.
🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.
#BladderCancer #GUOnc @OncoAlert @BladderCancerUS
¡¡La alegría del mes!! Los ciclistas lo agradecemos enormemente 🥲
Alberto Sánchez-Camacho retweeted
Original Article: Perioperative Apalutamide in High-Risk Localized Prostate Cancer (phase 3 PROTEUS trial) nej.md/3RuNe00
Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW
#Oncology #Urology
ALT This image contains four graphs showing the key secondary end points. Graph A shows event-free survival over time in months since randomization comparing ADT plus apalutamide and ADT plus placebo. Graph B presents the first subsequent local or systemic therapy occurrence, with the same treatment comparison. Graph C illustrates distant metastasis or conventional imaging or PSMA PET. Graph D compares freedom from disease at four years with percentages for both treatment groups. Each graph includes shaded confidence intervals and hazard ratios with confidence intervals.
Alberto Sánchez-Camacho retweeted
Me gusta muchísimo la nueva campaña de turismo de Castilla-La Mancha. Elegante, bien orientada, diseño precioso. Muy buena.
Alberto Sánchez-Camacho retweeted
Durvalumab + BCG is FDA approved in high risk NMIBC , by hitting its DFS - HR 0.68 (plus a ~⬇️ cystectomy rate). OS & M1 data show these patients have low cancer mortality & IO has about a 10% chance of serious side effects. Therefore, this is not a treatment for all HR NMIBC IMO. It’s hard to know who to select. Inconsistency with other data for Sasanlimab + atezo means there is no subset that consistently benefits. It will be interesting to see whom urologists recommend for treatment. #ASCO26 astrazeneca.com/content/astr…
Alberto Sánchez-Camacho retweeted
Aspirin & cancer prevention—myth or fact? 🤔
A @JAMAOnc paper👉
doi:10.1001/jamaoncol.2025.6196
In adults ≥70, 4.7 yrs of low-dose aspirin didn’t lower cancer risk and may increase cancer-related deaths during treatment. No long-term benefit seen.
@OncoAlert #cancer #oncology
Alberto Sánchez-Camacho retweeted
1/Proud to present this rewarding @GustaveRoussy + @DanaFarber collaboration in @NatureMedicine
We identify sMAdCAM-1 as a powerful prognostic biomarker in metastatic renal cell carcinoma, linking gut microbiota, immune resistance, and survival outcomes
@CarolinaAlvesC5 @oncoclinicas +@MarcMachaalani @ReneeSaliby @DanaFarber_GU @YaleIMed (co-1st)
#LaurenceZitvogel @AlbigesL (my co-seniors) – at Boston, MA
Alberto Sánchez-Camacho retweeted
Gracias @graficatessen !!!🤗 – at Cambridge, England
Alberto Sánchez-Camacho retweeted
Este #Movember no solo hablamos de prevención. En @sogug1 ponemos foco en algo igual de clave:
👀 Dar visibilidad al #cáncergenitourinario.
Próstata, riñón, vejiga: alta incidencia, gran impacto… y aún poco reconocimiento.
Visibilizar = avanzar 💙
#SaludMasculina #OncologíaGU
Alberto Sánchez-Camacho retweeted
1/🚨 First-line breakthrough in la/mUC HER2+ 🇨🇳
DV + toripalimab significantly improves PFS (HR 0.36) and OS (HR 0.54) vs chemo.
Striking efficacy across subgroups, including HER2 IHC1+, with a favorable safety profile.
🔜 A new SOC?
#ESMO25 @Uromigos @tompowles1
Gran pena la de hoy.
Me quedo con la frase “mi vida es más bonita gracias a ti” Selu (o Juan o Manuel o Juani)
Hoy es un día triste para el mundo del carnaval, uno de sus hijos mas grande se retira ( espero que no pa simpre) @elseludecadi GRACIAS POR TODO LO QUE NOS HAS DADO ,te lo digo públicamente mi vida ha sio mas bonita gracias a ti y a tu arte
Alberto Sánchez-Camacho retweeted
⚡️LBA⚡️POTOMAC: Ph 3 RCT of Durva + BCG for BCG-naïve HR NMIBC @urotoday #ESMO25 @mdesantis234
🎉 Positive Trial
☑️Prim EP DFS Durva + BCG (I+M) vs BCG (I+M): HR 0.68, 95% CI 0.50–0.93
☑️Sec EP DFS Durva + BCG (I only) versus BCG (I+M): HR 1.14, 95% CI 0.86–1.50
☑️Gr 3/4 TRAEs: 21% Durva + BCG (I+M), 15% Durva + BCG (I only), 4% BCG (I+M)
Alberto Sánchez-Camacho retweeted
🎯 NMIBC positive ph3 study Durva + BCG upfront for HR population! However Alban ph3 study in same population was negative! 🤷♂️ @myESMO @OncoAlert @OncBrothers #ESMO25
